| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Peroxisome proliferator-activated receptor delta |
|---|
| Ligand | BDBM50511193 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_1844146 (CHEMBL4344573) |
|---|
| EC50 | >100000±n/a nM |
|---|
| Citation |  Dou, X; Nath, D; Shin, H; Nurmemmedov, E; Bourne, PC; Ma, JX; Duerfeldt, AS Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPAR? Agonists as Leads for Retinal Disorders. J Med Chem63:2854-2876 (2020) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Peroxisome proliferator-activated receptor delta |
|---|
| Name: | Peroxisome proliferator-activated receptor delta |
|---|
| Synonyms: | NR1C2 | NUC1 | NUCI | Nuclear hormone receptor 1 | Nuclear receptor subfamily 1 group C member 2 | PPAR delta | PPAR-beta | PPARB | PPARD | PPARD_HUMAN | Peroxisome proliferator-activated receptor | Peroxisome proliferator-activated receptor beta | Peroxisome proliferator-activated receptor delta |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 49910.45 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q03181 |
|---|
| Residue: | 441 |
|---|
| Sequence: | MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSSPPSLLDQLQM
GCDGASCGSLNMECRVCGDKASGFHYGVHACEGCKGFFRRTIRMKLEYEKCERSCKIQKK
NRNKCQYCRFQKCLALGMSHNAIRFGRMPEAEKRKLVAGLTANEGSQYNPQVADLKAFSK
HIYNAYLKNFNMTKKKARSILTGKASHTAPFVIHDIETLWQAEKGLVWKQLVNGLPPYKE
ISVHVFYRCQCTTVETVRELTEFAKSIPSFSSLFLNDQVTLLKYGVHEAIFAMLASIVNK
DGLLVANGSGFVTREFLRSLRKPFSDIIEPKFEFAVKFNALELDDSDLALFIAAIILCGD
RPGLMNVPRVEAIQDTILRALEFHLQANHPDAQYLFPKLLQKMADLRQLVTEHAQMMQRI
KKTETETSLHPLLQEIYKDMY
|
|
|
|---|
| BDBM50511193 |
|---|
| n/a |
|---|
| Name | BDBM50511193 |
|---|
| Synonyms: | CHEMBL4466987 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C21H17F2NO3 |
|---|
| Mol. Mass. | 369.3614 |
|---|
| SMILES | OC(=O)c1cccc(NCc2ccc(OCc3ccc(F)cc3F)cc2)c1 |
|---|
| Structure | 
|
|---|
Search and Browse
